Copyright
©The Author(s) 2015.
World J Hematol. Aug 6, 2015; 4(3): 16-53
Published online Aug 6, 2015. doi: 10.5315/wjh.v4.i3.16
Published online Aug 6, 2015. doi: 10.5315/wjh.v4.i3.16
Clinical CM criteria JAK2 wild type PMGM | Pathological ECP criteria of CALR MGM |
A1 No preceding or allied other subtype of myeloproliferative neoplasm PV, CML, MDS. The main presenting features is pronounced isolated thrombocythemia with platelet count around or above 1000 × 109/L | P1 PMGM and relative or absolute reduction of erythropoiesis and erythroid precursors. Abnormal dense clustering and increase in atypical medium sized, large to giant immature megakaryocytes containing bulbous (cloud-like) hypolobulated nuclei and definitive maturation defects |
A2 Presence of CALR mutation and JAK2 wild type | |
C Clinical stages of CALR MGM | MF Grading RF, MF |
C1 Early clinical stage: Hb > 12 g/dL, slight to moderate splenomegaly, thrombocytosis around or above 1000 × 109/L, normal LAP score | MF 0 Prefibrotic CALR MGM, no reticulin fibrosis RF 0/1 |
C2 Intermediate clinical stage: slight anemia Hb < 12 to > 10 g/dL, decreasing platelet count, splenomegaly, increased LDH and definitive tear drop erythrocytes | MF 1 Early fibrotic CALR MGM slight reticulin fibrosis RF 2 |
C3 Advanced stage: anemia Hb < 10 g/dL, tear drop erythrocytes, increased LDH, increased CD34+ cells, pronounced splenomegaly, normal or decreased platelet counts, leucocytosis or leukopenia | MF 2 Fibrotic CALR MGM increase RF grade 3 and slight to moderate collagen fibrosis |
MF 3 Advanced fibrotic CALR MGM with collagen fibrosis-osteosclerosis |
-
Citation: Michiels JJ, Valster F, Wielenga J, Schelfout K, Raeve HD. European
vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms. World J Hematol 2015; 4(3): 16-53 - URL: https://www.wjgnet.com/2218-6204/full/v4/i3/16.htm
- DOI: https://dx.doi.org/10.5315/wjh.v4.i3.16